CTOR (Citius Oncology) Interest Expense: $-0.30 Mil (TTM As of Mar. 2026)


CTOR Citius Oncology Inc CTOR
10 GF Score
Price $0.63
! 2 Warning Signs
View Full Analysis

What is Citius Oncology Interest Expense?

Citius Oncology CTOR -6.07% 10 Interest Expense is $-0.30 Mil as of Mar. 2026. GuruFocus rates CTOR with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Citius Oncology's interest expense for the three months ended in Mar. 2026 was $ -0.03 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.30 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Citius Oncology's Operating Income for the three months ended in Mar. 2026 was $ -28.61 Mil. Citius Oncology's Interest Expense for the three months ended in Mar. 2026 was $ -0.03 Mil. Citius Oncology did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Citius Oncology  (NAS:CTOR) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Citius Oncology's Interest Expense for the three months ended in Mar. 2026 was $-0.03 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-28.61 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $3.80 Mil.

Citius Oncology's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Citius Oncology did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Citius Oncology Interest Expense Historical Data

* Premium members only.

The historical data trend for Citius Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Citius Oncology Interest Expense Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24 Sep25
Interest Expense
0.00 0.00 0.00 -0.22

Citius Oncology Quarterly Data
Sep22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.16 -0.06 -0.05 -0.03
CTOR
10GF Score
Citius Oncology Inc CTOR
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Citius Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.30 Mil mean?
Citius Oncology (CTOR) has a Interest Expense of $-0.30 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Citius Oncology and its competitors.
Is Citius Oncology's Interest Expense too high?
Citius Oncology's current Interest Expense is $-0.30 Mil. Overall, Citius Oncology has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Citius Oncology's Interest Expense compare to INCR and BGM?
Citius Oncology's Interest Expense of $-0.30 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Citius Oncology and its competitors. Citius Oncology's current Interest Expense is $-0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Citius Oncology stock overvalued right now?
Citius Oncology (CTOR) has a current Interest Expense of $-0.30 Mil. The current Interest Expense is $-0.30 Mil. Citius Oncology's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Citius Oncology (CTOR), the current Interest Expense is $-0.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Citius Oncology Business Description

Address 11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
10GF Score

Get the complete analysis for CTOR

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.63
Price